Search

Displaying results 9751 - 9760 of 10000 in total
  1. Drug

    Beludavimab

    go.drugbank.com/drugs/DB18952
    Investigational

    Beludavimab is under investigation in clinical trial NCT04746183 (AGILE (Early Phase Platform Trial for COVID-19)).

  2. Drug

    Sanfetrinem cilexetil

    go.drugbank.com/drugs/DB19135
    Investigational

    Sanfetrinem cilexetil is under investigation in clinical trial NCT05388448 (EBA, Safety and Tolerability of Sanfetrinem Cilexetil).

  3. Drug

    Acemannan

    go.drugbank.com/drugs/DB19224
    Investigational

    Acemannan is under investigation in clinical trial NCT03250923 (Celagace™ Orarinse Solution for Treatment of Candidiasis).

  4. Drug

    Tovecimig

    go.drugbank.com/drugs/DB30220
    Investigational

    NOV1501 is under investigation in clinical trial NCT03292783 (This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended … NOV1501 is a biologic drug.

  5. Drug

    Plamotamab

    go.drugbank.com/drugs/DB18944
    Investigational

    Plamotamab is under investigation in clinical trial NCT05328102 (Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (

  6. Drug

    LNP-nCoVsaRNA Vaccine

    go.drugbank.com/drugs/DB15799
    Experimental

    The vaccine was developed in and tested by the Medical Research Council Clinical Trials Unit at UCL in the UK, and jointly funded by UK Research and Innovation. … LNP-nCoVsaRNA is a purified, synthetic mRNA vaccine candidate encoding the S glycoprotein of SARS-CoV-2, which is used primarily by the virus to attach to and invade human cells.

  7. Drug

    Nomifensine

    go.drugbank.com/drugs/DB04821
    ApprovedWithdrawn

    The approved application holder removed Merital capsules from the market on January 23, 1986. … Nomifensine, formerly marketed as Merital capsules, was associated with an increased incidence of hemolytic anemia.

  8. Drug

    ENTR-601-44

    go.drugbank.com/drugs/DB17836
    Investigational

    ENTR-601-44 is an exon 44 skipping phosphorodiamidate morpholino oligonucleotide (PMO). Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy.[L46641]

  9. Drug

    GB-13

    go.drugbank.com/drugs/DB18387
    Experimental

    GB-13 is a genetically engineered recombinant protein consisting of an IL13Ra2-targeted genetically engineered mutant of IL-13 and PE4E, a derivative of Pseudomonas exotoxin A.

  10. Drug

    Candoxatrilat

    go.drugbank.com/drugs/DB11623
    Experimental

    A potent inhibitor of neutral endopeptidase (NEP, neprilysin, EC 3.4.24.11), it is used as its 2,3-dihydro-1H-inden-5-yl ester prodrug in the treatment of chronic heart failure.